F2G: Advancing Antifungal R&D




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: F2G: Advancing Antifungal R&D
Released on: October 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases.
  • Summary
  • Participants
  • Company
F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system. As a result serious fungal infections continue to increase. Ian Nicholson discusses with Fintan Walton F2G's aim to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates.
Ian has over 25 years of international experience in management and transactions within the life sciences sector. In addition to his role at F2G, he is currently an Operating Partner of London-based Advent Life Sciences LLP. Ian previously spent eight years as CEO of the privately held oncology R&D company, Chroma Therapeutics Limited. Prior to that he was Senior Vice President, Business Development at UK biotechnology company Celltech Group plc. Ian has worked extensively in licensing, M&A and market development in the UK, Europe and the US and holds a BSc (Hons.) from University College London and an MBA from Boston University. He holds Board positions at Consort Medical plc, Clinigen Group plc and Bioventix plc.
F2G is an established UK Biotech focusing on the discovery and development of novel drugs to treat life threatening fungal diseases. Fungal infection typically affects the immune-compromised patient where mortality rates are often very high. This patient population is increasing year by year due to increased cases of cancer, organ transplants and the use of potent medicines that affect the immune system. As a result serious fungal infections continue to increase. The focus at F2G is to serve the current unmet medical need by developing drugs that target the most difficult to treat fungi, especially those with the highest mortality rates. Through its proprietary genomics technology and antifungal screening activities F2G has identified a number of novel chemical series with potent antifungal activity. These novel series form the basis of the F2G development pipeline. Currently F2G is advancing its F3 series of anti mould compounds. This is a novel class of antifungal agent, which acts through a completely new mechanism different from all currently marketed drugs. The F3 series displays highly potent activity against clinically relevant aspergilli and many other important pathogenic moulds. F2G has a dedicated team of experienced scientists from a wide variety of research and drug development backgrounds supported by an experienced management group with many years experience of drug development within the Pharmaceutical industry.